AKT1 and COVID-19: Whether the currently proposed drugs targeting the Akt/mTOR pathway can be indeed repurposed for COVID-19 therapies now needs to be tested carefully in in vitro SARS-CoV-2 infection models and in in vivo COVID-19 disease models as improper regulation may pose a detrimental effect.